Head and Neck Cancer
Stories
-
FDA grants accelerated approval to Rybrevant Faspro for head and neck squamous cell carcinoma; ORR 42 percent
The FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and an anti-PD-(L)1 antibody; the overall response rate was 42 percent in 102 patients.
-
FDA approves RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval to RYBREVANT FASPRO, a co-formulated amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.